Certara reports Q3 adjusted EPS 13c, consensus 11c

Reports Q3 revenue $94.8M, consensus $95.5M. “Certara’s (CERT) results demonstrated strength in biosimulation software and services which are the result of our continued investment in biosimulation,” said William F. Feehery, Chief Executive Officer. “Following the close of the Chemaxon transaction, we are focused on integrating our software capabilities to generate a best-in-class, lab-to-clinic biosimulation platform.”